Organon (OGN) Non-Current Deferred Tax Liability (2020 - 2026)
Organon (OGN) recorded quarterly Non-Current Deferred Tax Liability of $56.0 million in Q1 2026, down 1.75% quarter-over-quarter from $57.0 million in Q4 2025, and down 18.84% on a YoY basis from $69.0 million in Q1 2025.
Organon (OGN) Non-Current Deferred Tax Liability (2020 - 2026) Analysis & Trends
Organon's Non-Current Deferred Tax Liability history runs 7 years deep, the most recent figure standing at $56.0 million for Q1 2026.
- In Q1 2026, Non-Current Deferred Tax Liability fell 18.84% year-over-year to $56.0 million; the TTM figure through Mar 2026 stood at $56.0 million (down 18.84% YoY), while the FY2025 annual figure was $57.0 million, down 65.24% from the prior year.
- Non-Current Deferred Tax Liability was $56.0 million for Q1 2026 at Organon, down from $57.0 million in the prior quarter.
- In the past five years, Non-Current Deferred Tax Liability ranged from a high of $164.0 million in Q4 2024 to a low of $2.0 million in Q1 2022.
- Historically, Non-Current Deferred Tax Liability has averaged $51.5 million across 5 years, with a median of $47.0 million in 2023.
- The sharpest annual moves came in 2022 and 2023: Non-Current Deferred Tax Liability sank 98.4% in 2022, then surged 1400.0% in 2023.
- A 5-year view of Non-Current Deferred Tax Liability shows it stood at $19.0 million in 2022, then jumped by 147.37% to $47.0 million in 2023, then soared by 248.94% to $164.0 million in 2024, then sank by 65.24% to $57.0 million in 2025, then retreated by 1.75% to $56.0 million in 2026.
- The last three Non-Current Deferred Tax Liability figures came in at $56.0 million (Q1 2026), $57.0 million (Q4 2025), and $62.0 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Gsk | 93,026,132.38 Bn | 93,026,127.42 Bn | 7.76 Bn |
| 2 | Eli Lilly | 1,022.62 Bn | 1,017.34 Bn | 16.22 Bn |
| 3 | Johnson & Johnson | 570.65 Bn | 548.59 Bn | 15.96 Bn |
| 4 | AbbVie | 398.73 Bn | 389.38 Bn | 10.78 Bn |
| 5 | Merck | 295.53 Bn | 289.88 Bn | 12.09 Bn |
| 6 | Amgen | 186.30 Bn | 174.26 Bn | 5.87 Bn |
| 7 | Gilead Sciences | 155.93 Bn | 148.21 Bn | 5.52 Bn |
| 8 | Pfizer | 146.09 Bn | 133.32 Bn | -1.21 Bn |
| 9 | Bristol Myers Squibb | 114.98 Bn | 104.53 Bn | 8.07 Bn |
| 10 | Organon | 3.49 Bn | 2.37 Bn | 783.00 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 56.00 Mn |
| Mar 31, 2026 | 56.00 Mn |
| Dec 31, 2025 | 57.00 Mn |
| Dec 31, 2025 | 57.00 Mn |
| Sep 30, 2025 | 62.00 Mn |
| Sep 30, 2025 | 62.00 Mn |
| Jun 30, 2025 | 69.00 Mn |
| Jun 30, 2025 | 69.00 Mn |
| Mar 31, 2025 | 69.00 Mn |
| Mar 31, 2025 | 69.00 Mn |
| Dec 31, 2024 | 164.00 Mn |
| Dec 31, 2024 | 164.00 Mn |
| Sep 30, 2024 | 56.00 Mn |
| Sep 30, 2024 | 56.00 Mn |
| Jun 30, 2024 | 60.00 Mn |
| Jun 30, 2024 | 60.00 Mn |
| Mar 31, 2024 | 44.00 Mn |
| Mar 31, 2024 | 44.00 Mn |
| Dec 31, 2023 | 47.00 Mn |
| Dec 31, 2023 | 47.00 Mn |